Danielczyk W
Z Gerontol. 1984 Sep-Oct;17(5):280-4.
Parkinson's disease is an illness occurring in the third stage of life. At times, the patient suffers from arteriosclerosis as well. Reconstruction processes caused by aging are under way in the brain, which affect, among others, the synapses and transmitter substances. The biotransformation of medication may be changed in elderly persons. The tendency to multimorbidity leads to consumption of several drugs at the same time, possibly causing interference symptoms. Changes in transmitter balance and receptor excitability are, however, the main causes of the toxic side-effects of anti Parkinson therapy. The greater the nigrostriatal degeneration, the lower the tolerance level. Recently, in addition to basic therapy consisting of reduced doses of combined dopa preparations and/or Amantadine sulphate, dopaminergic agonists are used, which act on the receptors which have been maintained. This prevents some side-effects and stabilizes the patient's unpleasant daily fluctuations. Reducing the dosage prevents dyskinesia. pharmacotoxic psychoses require neuroleptics of the Thiaxanthen group or change-over to i.v. Amantadine sulphate infusions or Lisuride i.v.
帕金森病是一种在人生第三阶段出现的疾病。有时，患者还患有动脉硬化。大脑中由衰老引起的重建过程正在进行，这尤其会影响突触和神经递质。老年人的药物生物转化可能会发生变化。多病共存的倾向导致同时服用多种药物，可能会引发干扰症状。然而，神经递质平衡和受体兴奋性的变化是抗帕金森治疗毒性副作用的主要原因。黑质纹状体变性越严重，耐受性水平越低。最近，除了由减量的复方多巴制剂和/或硫酸金刚烷胺组成的基础治疗外，还使用多巴胺能激动剂，其作用于尚存的受体。这可预防一些副作用，并稳定患者令人不适的日常波动。减少剂量可预防运动障碍。药物毒性精神病需要使用噻吨类神经阻滞剂，或改用静脉注射硫酸金刚烷胺或静脉注射利苏瑞肽。
